论文部分内容阅读
选取2型糖尿病合并脑血管病病人36例,随机分为瑞格列奈组,对照组,治疗前、后检测空腹和餐后2h血糖,糖化血清蛋白(GSP)、血胆固醇(TC)、血甘油三脂(TG),肝、肾功能、血压、体重、低血糖发生率。结果:瑞格列奈组FPG,PPG2h,GSP,治疗前后差异P<0.05,低血糖发生率5%。胰岛素组治疗前后FPG,PPG2h,GSP,治疗前后差异P<0.05,低血糖发生率18.8%。两组比较低血糖发生率有统计学意义,P<0.05。结论:在2型糖尿病合并脑血管病患者中与常规胰岛素治疗相比瑞格列奈亦可迅速、安全降糖,但在低血糖发生率明显低于胰岛素治疗组。
Thirty-six type 2 diabetic patients with cerebrovascular disease were selected and randomly divided into repaglinide group, control group, fasting and postprandial blood glucose, glycosylated serum protein (GSP), blood cholesterol (TC), blood Triglyceride (TG), liver, kidney function, blood pressure, body weight, incidence of hypoglycemia. Results: The levels of FPG, PPG2h and GSP in repaglinide group before and after treatment were P <0.05, and the incidence of hypoglycemia was 5%. The levels of FPG, PPG2h and GSP in the insulin group before and after treatment were P <0.05 before and after treatment, and the incidence of hypoglycemia was 18.8%. The incidence of hypoglycemia in both groups was statistically significant, P <0.05. CONCLUSIONS: Repaglinide is also rapidly and safely hypoglycemic in patients with type 2 diabetes mellitus and cerebrovascular disease compared with conventional insulin therapy, but the incidence of hypoglycemia is significantly lower than that in insulin-treated patients.